Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 74

Sort by

Sort Order Select

Journal Articles

Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy

Levani Odikadze, MD MPH, Nisha Joseph, MD, Timothy M. Schmidt, MD, Leonard Heffner, MD, Craig C Hofmeister, MD MPH, Madhav V Dhodapkar, MD, Vikas A. Gupta, MD PhD, Lawrence H. Boise, PhD, David L. Jaye, MD, Sagar Lonial, MD, Ajay K Nooka, MD MPH, Jonathan L Kaufman, MD

Blood (2018) 132 (Supplement 1): 1884.

https://doi.org/10.1182/blood-2018-99-114368

Published: 2018

Journal Articles

Outcomes of Myeloma Patients with t(11;14) Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy

Jonathan L Kaufman, MD, Nisha Joseph, MD, Vikas A. Gupta, MD PhD, Charise Gleason, ANP, Craig C Hofmeister, MD MPH, Leonard Heffner, MD, Madhav V Dhodapkar, MD, Sagar Lonial, MD, Lawrence H. Boise, PhD, Ajay K Nooka, MD MPH

Blood (2018) 132 (Supplement 1): 3282.

https://doi.org/10.1182/blood-2018-99-119051

Published: 2018

Journal Articles

Outcomes and Clinical Features of Patients with 1q+ Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone

Timothy M. Schmidt, MD, Nisha Joseph, MD, Levani Odikadze, MD MPH, Leonard Heffner, MD, Craig C Hofmeister, MD MPH, Madhav V Dhodapkar, MD, Vikas A. Gupta, MD PhD, Lawrence H. Boise, PhD, David L. Jaye, MD, Sagar Lonial, MD, Ajay K Nooka, MD MPH, Jonathan L Kaufman, MD

Blood (2018) 132 (Supplement 1): 3241.

https://doi.org/10.1182/blood-2018-99-112216

Published: 2018

Journal Articles

Efficacy of Induction Thearapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients

Nisha Joseph, MD, Vikas A. Gupta, MD PhD, Craig C Hofmeister, MD MPH, Charise Gleason, ANP, Leonard Heffner, MD, Lawrence H. Boise, PhD, Jonathan L Kaufman, MD, Madhav V Dhodapkar, MD, Sagar Lonial, MD, Ajay K Nooka, MD MPH

Blood (2018) 132 (Supplement 1): 3294.

https://doi.org/10.1182/blood-2018-99-119895

Published: 2018

Journal Articles

Impact of Early Progression on Long Term Outcomes Among Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy

Ajay K Nooka, MDMPH, Jonathan L Kaufman, MD, Charise Gleason, ANP, Nisha Joseph, MD, Craig C Hofmeister, MD MPH, Lawrence H. Boise, PhD, Leonard Heffner, MD, Madhav V Dhodapkar, MD, Sagar Lonial, MD

Blood (2018) 132 (Supplement 1): 3302.

https://doi.org/10.1182/blood-2018-99-120314

Published: 2018

Journal Articles

Safety and Efficacy of Evomela™ in Myeloma Autotransplants

Kimberly Amelsberg, Nisha Joseph, MD, Amelia Langston, MD, Jonathan L Kaufman, MD, Craig C Hofmeister, MD MPH, Edmund K. Waller, MD, Michael Graiser, PhD, Robin Larocco, Leonard Heffner, MD, Madhav V Dhodapkar, MD, Sagar Lonial, MD, Ajay K Nooka, MD MPH

Blood (2018) 132 (Supplement 1): 3446.

https://doi.org/10.1182/blood-2018-99-119730

Published: 2018

Journal Articles

Differences in Presentation and Survival Outcomes for African American Patients with Newly Diagnosed Multiple Myeloma

Blood (2018) 132 (Supplement 1): 5647.

https://doi.org/10.1182/blood-2018-99-119948

Published: 2018

Journal Articles

The Impact of a Physical Activity Intervention Can be Accurately Assessed By Smart Watches in Patients Completing Autologous Stem Cell Transplantation for Lymphoma or Multiple Myeloma: Results of a Feasibility Study

Blood (2018) 132 (Supplement 1): 5911.

https://doi.org/10.1182/blood-2018-99-119757

Published: 2018

Journal Articles

Lenalidomide and Vorinostat Maintenance after Autologous Transplant in Multiple Myeloma- Long Term Follow-up

Nidhi Sharma, PhD MS, Nita Williams, BS, Ashley E. Rosko, MD, Don M. Benson, Jr., MD PhD, Maria Chaudhry, MD, Craig C Hofmeister, MD MPH, Douglas W. Sborov, MD MS, Yvonne Efebera, MD

Blood (2018) 132 (Supplement 1): 2155.

https://doi.org/10.1182/blood-2018-99-116460

Published: 2018

Journal Articles

G-CSF Starting Day +1 after Autologous Transplant Is Safer Than Day +5 or Day +7 in Patients with Multiple Myeloma

Francesca Cottini, Douglas Sborov, Yu Kyoung Cho, Misty Lamprecht, Karen Tackett, Junan Li, Steven M. Devine, Ming Poi, Mitch A. Phelps, Craig C Hofmeister, MD MPH

Blood (2016) 128 (22): 5790.

https://doi.org/10.1182/blood.V128.22.5790.5790

Published: 2016

Journal Articles

Geriatric Assessment Metrics Are Associated with Hospital Length of Stay in Pre-Bone Marrow Transplant Myeloma Patients

Ashley E Rosko, MD, Craig C Hofmeister, MD MPH, Yvonne A Efebera, MD, Don M Benson, MD PhD, Douglas W Sborov, MD MS, Samantha Jaglowski, MD MPH, Steve Devine, MD, Tanya M Wildes, MD MSCI, James Gillahan, Desiree Jones, Ying Huang, MA, MS, Christin E Burd, PhD

Blood (2015) 126 (23): 3200.

https://doi.org/10.1182/blood.V126.23.3200.3200

Published: 2015

Journal Articles

Phase 2 Study of Carfilzomib (CFZ) with or without Filanesib (FIL) in Patients with Advanced Multiple Myeloma (MM)

Blood (2015) 126 (23): 728.

https://doi.org/10.1182/blood.V126.23.728.728

Published: 2015

Journal Articles

Small RNA Deep Sequencing Highlights the Important Contribution of Mirnas in Regulating IRF4/c-Myc Axis in Myeloma Development

Hanna Radomska, Alessandro Canella, Consiglio Jessica, Alberto Rocci, MD, Cascione Luciano, Hector Cordero, Liu Joseph, Enrico Caserta, Santhanam Ramasamy, Yvonne A. Efebera, MD MPH, Stefano Volinia, PhD, Craig C Hofmeister, MD MPH, Flavia Pichiorri, PhD

Blood (2015) 126 (23): 1791.

https://doi.org/10.1182/blood.V126.23.1791.1791

Published: 2015

Journal Articles

Reolysin Combined with Carfilzomib for Treatment of Relapsed Multiple Myeloma Patients

Douglas W Sborov, MD MS, Flavia Pichiorri, PhD MSC, Gerard J Nuovo, MD, Don M Benson, MD PhD, Yvonne A. Efebera, MD MPH, Ashley E Rosko, MD, Craig C Hofmeister, MD MPH

Blood (2015) 126 (23): 1835.

https://doi.org/10.1182/blood.V126.23.1835.1835

Published: 2015

Journal Articles

Proteomic Characterization of Circulating Extracellular Vesicles Identifies Novel Serum Myeloma Associated Markers

David Ciarlariello, Sean Harshman, Alessandro Canella, Erinn Hade, Alberto Rocci, MD, Antonio Palumbo, MD, Craig C Hofmeister, MD MPH, Michael Freitas, Don M Benson, MD PhD, Flavia Pichiorri, PhD

Blood (2015) 126 (23): 1814.

https://doi.org/10.1182/blood.V126.23.1814.1814

Published: 2015

Journal Articles

TG02, an Oral CDK9-Inhibitor, in Combination with Carfilzomib Demonstrated Objective Responses in Carfilzomib Refractory Multiple Myeloma Patients

Craig C Hofmeister, MD MPH, Jesus G. Berdeja, MD, David H. Vesole, MD PhD, Attaya Suvannasankha, MD, Tracy Parrott, Rafat Abonour, MD

Blood (2015) 126 (23): 3052.

https://doi.org/10.1182/blood.V126.23.3052.3052

Published: 2015

Journal Articles

The Majority of Myeloma Patients Are Hypogonadal but This Is Not Associated with High Risk Cytogenetics

Beau Snoad, Samantha Hudzik, Douglas W Sborov, MD MS, Nita Williams, Desiree Jones, Craig C Hofmeister, MD MPH

Blood (2015) 126 (23): 5329.

https://doi.org/10.1182/blood.V126.23.5329.5329

Published: 2015

Journal Articles

The Majority of Myeloma Patients Are Vitamin D Deficient, Unrelated to Survival or Cytogenetics

Samantha Hudzik, Beau Snoad, Luay Mousa, MD, Douglas W Sborov, MD MS, Nita Williams, Desiree Jones, Craig C Hofmeister, MD MPH

Blood (2015) 126 (23): 5336.

https://doi.org/10.1182/blood.V126.23.5336.5336

Published: 2015

Journal Articles

Selinexor Demonstrates Marked Synergy with Dexamethasone (Sel-Dex) in Preclinical Models and in Patients with Heavily Pretreated Refractory Multiple Myeloma (MM)

Blood (2014) 124 (21): 4773.

https://doi.org/10.1182/blood.V124.21.4773.4773

Published: 2014

Journal Articles

HDAC Inhibitor AR-42 Decreases CD44 Expression and Sensitizes Myeloma Cells to Lenalidomide

Hector Cordero-Nieves, BS, Douglas W. Sborov, MD, Alessandro Canella, MS, Zhongfa Liu, Jessica Consiglio, MS, Wenjun Ni, Emily Smith, Lara Rizzotto, PhD, Yvonne A Efebera, MD, Don M. Benson, MD PhD, Luciano Cascione, Mo Xiaokui, MS, John C. Byrd, MD, Michael R. Grever, MD, Craig C Hofmeister, MD MPH, Flavia Pichiorri, PhD

Blood (2014) 124 (21): 3377.

https://doi.org/10.1182/blood.V124.21.3377.3377

Published: 2014

NARROW

Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy

Outcomes of Myeloma Patients with t(11;14) Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy

Outcomes and Clinical Features of Patients with 1q+ Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone

Efficacy of Induction Thearapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients

Impact of Early Progression on Long Term Outcomes Among Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy

Safety and Efficacy of Evomela™ in Myeloma Autotransplants

Differences in Presentation and Survival Outcomes for African American Patients with Newly Diagnosed Multiple Myeloma

The Impact of a Physical Activity Intervention Can be Accurately Assessed By Smart Watches in Patients Completing Autologous Stem Cell Transplantation for Lymphoma or Multiple Myeloma: Results of a Feasibility Study

Lenalidomide and Vorinostat Maintenance after Autologous Transplant in Multiple Myeloma- Long Term Follow-up

G-CSF Starting Day +1 after Autologous Transplant Is Safer Than Day +5 or Day +7 in Patients with Multiple Myeloma

Geriatric Assessment Metrics Are Associated with Hospital Length of Stay in Pre-Bone Marrow Transplant Myeloma Patients

Phase 2 Study of Carfilzomib (CFZ) with or without Filanesib (FIL) in Patients with Advanced Multiple Myeloma (MM)

Small RNA Deep Sequencing Highlights the Important Contribution of Mirnas in Regulating IRF4/c-Myc Axis in Myeloma Development

Reolysin Combined with Carfilzomib for Treatment of Relapsed Multiple Myeloma Patients

Proteomic Characterization of Circulating Extracellular Vesicles Identifies Novel Serum Myeloma Associated Markers

TG02, an Oral CDK9-Inhibitor, in Combination with Carfilzomib Demonstrated Objective Responses in Carfilzomib Refractory Multiple Myeloma Patients

The Majority of Myeloma Patients Are Hypogonadal but This Is Not Associated with High Risk Cytogenetics

The Majority of Myeloma Patients Are Vitamin D Deficient, Unrelated to Survival or Cytogenetics

Selinexor Demonstrates Marked Synergy with Dexamethasone (Sel-Dex) in Preclinical Models and in Patients with Heavily Pretreated Refractory Multiple Myeloma (MM)

HDAC Inhibitor AR-42 Decreases CD44 Expression and Sensitizes Myeloma Cells to Lenalidomide

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only